Diagnostic Stewardship for Ventilator-Associated Pneumonia
Trial Summary
Do I have to stop taking my current medications to join the trial?
The trial protocol does not specify whether you need to stop taking your current medications. However, it focuses on antibiotic use, so it's possible that changes to your antibiotic regimen might be discussed with your healthcare provider.
What data supports the idea that Diagnostic Stewardship for Ventilator-Associated Pneumonia is an effective treatment?
The available research does not provide specific data on Diagnostic Stewardship for Ventilator-Associated Pneumonia. However, it does show that similar interventions, like optimizing blood culture practices, can reduce unnecessary testing and improve the accuracy of results. For example, in one study, the rate of blood cultures ordered decreased significantly, and the positivity rate increased, indicating more accurate testing. This suggests that Diagnostic Stewardship could potentially improve outcomes by ensuring more precise and necessary testing.12345
What safety data is available for the treatment of Diagnostic Stewardship for Ventilator-Associated Pneumonia?
The provided research does not contain specific safety data for the treatment of Diagnostic Stewardship for Ventilator-Associated Pneumonia or its related interventions like Modified lab reporting. The studies focus on the use of voluntary incident reporting systems to improve patient safety in the ICU, but they do not provide direct safety data for the specific treatment in question.678910
Is the treatment in the trial 'Diagnostic Stewardship for Ventilator-Associated Pneumonia' a promising treatment?
What is the purpose of this trial?
The goal of this pragmatic cluster-randomized crossover trial is to test if less unnecessary antibiotics are prescribed when the lab reports respiratory culture test results in a specific way for patients who have respiratory cultures obtained, but do not meet clinical criteria for ventilator associated pneumonia (VAP). The main question it aims to answer is: Does a modified culture reporting intervention reduce unnecessary antibiotics for ventilated patients in the intensive care unit (ICU)? Researchers will compare antibiotic use outcomes between eligible patients whose test results are communicated using the modified reporting and those with standard reporting of results.
Research Team
Surbhi Leekha, MD
Principal Investigator
University of Maryland, Baltimore
Eligibility Criteria
This trial is for adults over 18 who are in the ICU, on a ventilator, and have had a respiratory culture taken more than 48 hours after admission. It's not for patients with severe immune system issues, recent transplants or certain therapies, ECMO at culture time, prisoners, or if the lab rejected their sample.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Control Period
Laboratory reporting of respiratory cultures will continue per regular or routine laboratory protocols (standard reporting).
Intervention Period
The lab will publish a modified report for respiratory cultures which do not meet clinical criteria for pneumonia and have growth of organisms (other than normal respiratory flora).
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Modified lab reporting
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Maryland, Baltimore
Lead Sponsor
Centers for Disease Control and Prevention
Collaborator
George Washington University
Collaborator
Baylor College of Medicine
Collaborator
Virginia Commonwealth University
Collaborator